Released Mar 9, 2023, before the open
10-K filed Mar 9, 2023, 68 days after period end · 0001171843-23-001566
Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$28.43M$28.43M derived−14.0% vs Q4 2021+5.6% vs Q3 2022
Net Income-$1.67M-$1.67M derivedN/M vs Q4 2021N/M vs Q3 2022
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$15,833,000−19.1%
Operating Incomederived-$457,000N/M
Operating Cash Flowderived$2,679,000+2,189.7%
Free Cash Flowderived$2,444,000N/M
Margins · derived
Gross margin55.7%−3.5 pt vs Q4 2021
Operating margin-1.6%−6.7 pt vs Q4 2021
Net margin-5.9%−8.8 pt vs Q4 2021
What the release said
The release
Same quarter
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019 |
|---|---|---|---|---|
| Revenue | $28.43M | $33.06M | $30.98M | $30.97M |
| Net Income | -$1.67M | $961.00K | -$615.00K | $550.00K |
| EPS Diluted | — | — | — | $0.02 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Harvard Bioscience Inc · CIK 1123494 · Engraved from SEC EDGAR